{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:19Z","timestamp":1781647219851,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ursodeoxycholic acid (UDCA), used for treating cholestasis, was reported to protect against severe COVID-19 outcomes. We aimed to assess this potential effect using nationwide Swedish register data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We included all SARS-CoV-2 test-positive subjects aged\u2009\u2265\u200918 years during 2020\u20132023, with previous diagnosis of potentially UDCA-treated diseases, including primary biliary cholangitis, liver cirrhosis, autoimmune hepatitis, or cholangitis. Subjects who had filled a UDCA prescription within 6 months before testing positive were considered exposed. Subjects were followed from test-positivity to the earliest of analyzed outcome (COVID-19-related hospitalization, 30-day all-cause mortality, or COVID-19-related death), one year of follow-up, emigration, death, or end of 2023. Control for potential confounding (vaccination status, COVID-19 waves, prior comorbidities, and sociodemographics) was done by adjustment, propensity score weighting (PSW), and doubly robust analysis. Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (95%CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study cohort consisted of 833 UDCA-exposed and 3638 non-exposed individuals. The adjusted Cox analysis showed potentially decreased risks (non-significant) among UDCA-exposed for 30-day mortality (HR 0.62, 95%CI 0.34\u20131.13) and COVID-19 death (0.70, 0.37\u20131.32), but a smaller non-significant increased risk for hospitalization (1.19, 0.92\u20131.53). PSW achieved an adequate balance between exposed and non-exposed and showed similar results for 30-day mortality (0.78, 0.40\u20131.53), COVID-19 death (0.86, 0.43\u20131.71), and hospitalization (1.15, 0.81\u20131.61). The doubly robust method showed similar results as PSW.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study did not provide evidence supporting protective effects for severe COVID-19 outcomes. However, the results are limited by the small cohort of patients treated with UDCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-026-26908-1","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:33:10Z","timestamp":1775892790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ursodeoxycholic acid treatment did not show protective effect for severe COVID-19 outcomes \u2013 a nationwide register study"],"prefix":"10.1186","volume":"26","author":[{"given":"Huiqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailiana","family":"Santosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Nyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"26908_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","volume":"615","author":"T Brevini","year":"2023","unstructured":"Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023;615:134\u201342. https:\/\/doi.org\/10.1038\/s41586-022-05594-0.","journal-title":"Nature"},{"key":"26908_CR2","doi-asserted-by":"publisher","first-page":"175628482412657","DOI":"10.1177\/17562848241265782","volume":"17","author":"S Drazilova","year":"2024","unstructured":"Drazilova S, Koky T, Macej M, Janicko M, Simkova D, Jarcuska P. The treatment of primary biliary cholangitis: from shadow to light. Ther Adv Gastroenterol. 2024;17:17562848241265782. https:\/\/doi.org\/10.1177\/17562848241265782.","journal-title":"Ther Adv Gastroenterol"},{"key":"26908_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/joim.13630","volume":"293","author":"BV John","year":"2023","unstructured":"John BV, Bastaich D, Webb G, Brevini T, Moon A, Ferreira RD, et al. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis. J Intern Med. 2023;293:636\u201347. https:\/\/doi.org\/10.1111\/joim.13630.","journal-title":"J Intern Med"},{"key":"26908_CR4","doi-asserted-by":"publisher","first-page":"1178590","DOI":"10.3389\/fcimb.2023.1178590","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Zhu N, Cui X, Lin Y, Li X. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease. Front Cell Infect Microbiol. 2023;13:1178590. https:\/\/doi.org\/10.3389\/fcimb.2023.1178590.","journal-title":"Front Cell Infect Microbiol"},{"key":"26908_CR5","doi-asserted-by":"publisher","unstructured":"Hu L, Zhang H, Huang C, Shen T, Feng Z, Mu F, et al. Effect of Ursodeoxycholic Acid on Preventing SARS-CoV-2 Infection in Patients With Liver Transplantation: a multicenter retrospective cohort study. QJM Mon J Assoc Physicians. 2023;hcad254. https:\/\/doi.org\/10.1093\/qjmed\/hcad254.","DOI":"10.1093\/qjmed\/hcad254"},{"key":"26908_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13711","author":"L Ojeda-Fern\u00e1ndez","year":"2023","unstructured":"Ojeda-Fern\u00e1ndez L, Baviera M, Macaluso G, Schena S, Tettamanti M, Cartabia M, et al. UDCA treatment against COVID-19: Do we have enough clinical evidence for drug repurposing? J Intern Med. 2023. https:\/\/doi.org\/10.1111\/joim.13711.","journal-title":"J Intern Med"},{"key":"26908_CR7","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/liv.15660","volume":"43","author":"T Liu","year":"2023","unstructured":"Liu T, Wang J-S. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children. Liver Int Off J Int Assoc Study Liver. 2023;43:1950\u20134. https:\/\/doi.org\/10.1111\/liv.15660.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"26908_CR8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/v15081738","volume":"15","author":"F Colapietro","year":"2023","unstructured":"Colapietro F, Angelotti G, Masetti C, Shiffer D, Pugliese N, De Nicola S, et al. Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients. Viruses. 2023;15:1738. https:\/\/doi.org\/10.3390\/v15081738.","journal-title":"Viruses"},{"key":"26908_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2147\/CLEP.S312742","volume":"13","author":"F Nyberg","year":"2021","unstructured":"Nyberg F, Franz\u00e9n S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, et al. Swedish Covid-19 Investigation for Future Insights - A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL). Clin Epidemiol. 2021;13:649\u201359. https:\/\/doi.org\/10.2147\/CLEP.S312742.","journal-title":"Clin Epidemiol"},{"key":"26908_CR10","unstructured":"World Bank Country and Lending Groups \u2013 World Bank Data Help Desk. 2023. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed 15 Nov 2023."},{"key":"26908_CR11","doi-asserted-by":"crossref","unstructured":"Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Second ed. Berlin: Springer; 2015.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"26908_CR12","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657. https:\/\/doi.org\/10.1136\/bmj.l5657.","journal-title":"BMJ"},{"key":"26908_CR13","unstructured":"Ridgeway G, McCaffrey D, Morral A, Cefalu M, Burgette L, Griffin BA. Toolkit for Weighting and Analysis of Nonequivalent Groups: A guide to the twang package. 2023."},{"key":"26908_CR14","doi-asserted-by":"publisher","unstructured":"Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84-S90.e1. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.01.013","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"26908_CR15","doi-asserted-by":"publisher","first-page":"616381","DOI":"10.3389\/fped.2021.616381","volume":"9","author":"A Di Giorgio","year":"2021","unstructured":"Di Giorgio A, Hartleif S, Warner S, Kelly D. COVID-19 in Children With Liver Disease. Front Pediatr. 2021;9:616381. https:\/\/doi.org\/10.3389\/fped.2021.616381.","journal-title":"Front Pediatr"},{"key":"26908_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jpeds.2020.04.026","volume":"222","author":"E Nicastro","year":"2020","unstructured":"Nicastro E, Mazza A, Gervasoni A, Di Giorgio A, D\u2019Antiga L. A Pediatric Emergency Department Protocol to Avoid Intrahospital Spread of SARS-CoV-2 during the Outbreak in Bergamo, Italy. J Pediatr. 2020;222:231\u20135. https:\/\/doi.org\/10.1016\/j.jpeds.2020.04.026.","journal-title":"J Pediatr"},{"key":"26908_CR17","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.jhep.2023.06.011","volume":"79","author":"Z Li","year":"2023","unstructured":"Li Z, Hu Y, Zou B. The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis. J Hepatol. 2023;79:e157\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.011.","journal-title":"J Hepatol"},{"key":"26908_CR18","unstructured":"Hofmeister M, Stone EC, Okasako-Schmucker DL, Henry MC, Kumasaka J, Fellow O, et al. Brief Summary of Findings on the Association Between Underlying Liver Diseases and Severe COVID-19 Outcomes. 2025. https:\/\/www.cdc.gov\/covid\/media\/pdfs\/2025\/02\/B-ChronicLiverReview_Final.pdf"},{"key":"26908_CR19","doi-asserted-by":"publisher","first-page":"113568","DOI":"10.1016\/j.biopha.2022.113568","volume":"154","author":"P Li","year":"2022","unstructured":"Li P, Liu Y, Cheng Z, Yu X, Li Y. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother Biomedecine Pharmacother. 2022;154:113568. https:\/\/doi.org\/10.1016\/j.biopha.2022.113568.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"26908_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiol Camb Mass. 2008;19:766\u201379. https:\/\/doi.org\/10.1097\/EDE.0b013e3181875e61.","journal-title":"Epidemiol Camb Mass"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26908-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:49:34Z","timestamp":1781646574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26908-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26908"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26908-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is part of the SCIFI-PEARL project, and ethical approval was obtained from the Swedish Ethical Review Authority (Reference number 2020\u2009\u2212\u200901800 with subsequent amendments). As it is a register-based study, individual consent from participants was not required. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FN, AS, HL report participation in a research project funded by Bayer (regulator-mandated phase IV study), with funds paid to the University of Gothenburg where they are employed (no personal fees) and with no relation to the work reported here. FN owns some AstraZeneca shares. All other authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1240"}}